Brokerages Set AstraZeneca PLC (LON:AZN) PT at £116.86

Shares of AstraZeneca PLC (LON:AZN) have received an average recommendation of “Moderate Buy” from the nine analysts that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and six have assigned a buy rating to the company. The average 12 month price target among brokers that have covered the stock in the last year is £116.86 ($146.79).

A number of brokerages have issued reports on AZN. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Thursday, April 4th. Barclays reiterated an “overweight” rating and set a £125 ($157.02) price objective on shares of AstraZeneca in a research note on Monday, April 8th. Jefferies Financial Group reissued a “hold” rating and issued a £110 ($138.17) target price on shares of AstraZeneca in a research report on Friday, February 16th. BMO Capital Markets reaffirmed an “outperform” rating on shares of AstraZeneca in a research report on Monday, February 12th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a £105 ($131.89) price target on shares of AstraZeneca in a research note on Tuesday, April 23rd.

AstraZeneca Trading Down 0.9 %

LON:AZN opened at £120.50 ($151.36) on Tuesday. AstraZeneca has a one year low of GBX 9,461 ($118.84) and a one year high of £124.88 ($156.86). The business’s 50-day simple moving average is £107.67 and its 200 day simple moving average is £104.90. The company has a debt-to-equity ratio of 92.51, a quick ratio of 0.59 and a current ratio of 0.89. The stock has a market cap of £186.78 billion, a price-to-earnings ratio of 3,730.65, a price-to-earnings-growth ratio of 0.93 and a beta of 0.19.

AstraZeneca Increases Dividend

The business also recently declared a dividend, which was paid on Monday, March 25th. Investors of record on Thursday, February 22nd were issued a GBX 156 ($1.96) dividend. This is an increase from AstraZeneca’s previous dividend of $71.80. The ex-dividend date was Thursday, February 22nd. This represents a dividend yield of 1.49%. AstraZeneca’s dividend payout ratio (DPR) is 7,058.82%.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.